Dr. Reddy's Laboratories launches public offer to acquire OctoPlus shares
Dr. Reddy's Laboratories Limited (``Dr. Reddy's''), together with its subsidiaries, launches the recommended public offer to acquire all the issued and outstanding shares of OctoPlus NV, a service-based specialty pharmaceutical company, at an offer price of EUR 0.52 per share.
Biopharmaceutical company Orexigen Therapeutics Inc reported on Thursday the grant of an inducement stock option to a new employee to purchase 9,000 shares of common stock.